Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells

A. Pardanani; T. Lasho; D. Chen; T. K. Kimlinger; C. Finke; D. Zblewski; M. M. Patnaik; K. K. Reichard; E. Rowinsky; C. A. Hanson; C. Brooks; A. Tefferi

doi:10.1038/leu.2015.16

Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells

A. Pardanani, T. Lasho, D. Chen, T. K. Kimlinger, C. Finke, D. Zblewski, M. M. Patnaik, K. K. Reichard, E. Rowinsky, C. A. Hanson, C. Brooks, A. Tefferi

Research output: Contribution to journal › Letter › peer-review

19 Scopus citations

Original language	English (US)
Pages (from-to)	1605-1608
Number of pages	4
Journal	Leukemia
Volume	29
Issue number	7
DOIs	https://doi.org/10.1038/leu.2015.16
State	Published - Jul 13 2015

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2015.16

Cite this

@article{d3c091ee9f0d44e6b863925de5cb83d2,

title = "Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells",

author = "A. Pardanani and T. Lasho and D. Chen and Kimlinger, {T. K.} and C. Finke and D. Zblewski and Patnaik, {M. M.} and Reichard, {K. K.} and E. Rowinsky and Hanson, {C. A.} and C. Brooks and A. Tefferi",

note = "Funding Information: AP received research funding from Stemline Therapeutics Inc. for the flow cytometry experiments. AP is Principal Investigator for a forthcoming clinical trial of SL-401 for treatment of myeloproliferative neoplasms. SL-401 is a CD123-targeting investigational drug manufactured by Stemline Therapeutics Inc. CB and ER are employees of Stemline Therapeutics Inc.",

year = "2015",

month = jul,

day = "13",

doi = "10.1038/leu.2015.16",

language = "English (US)",

volume = "29",

pages = "1605--1608",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells

AU - Pardanani, A.

AU - Lasho, T.

AU - Chen, D.

AU - Kimlinger, T. K.

AU - Finke, C.

AU - Zblewski, D.

AU - Patnaik, M. M.

AU - Reichard, K. K.

AU - Rowinsky, E.

AU - Hanson, C. A.

AU - Brooks, C.

AU - Tefferi, A.

N1 - Funding Information: AP received research funding from Stemline Therapeutics Inc. for the flow cytometry experiments. AP is Principal Investigator for a forthcoming clinical trial of SL-401 for treatment of myeloproliferative neoplasms. SL-401 is a CD123-targeting investigational drug manufactured by Stemline Therapeutics Inc. CB and ER are employees of Stemline Therapeutics Inc.

PY - 2015/7/13

Y1 - 2015/7/13

UR - http://www.scopus.com/inward/record.url?scp=84937023038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937023038&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.16

DO - 10.1038/leu.2015.16

M3 - Letter

C2 - 25640886

AN - SCOPUS:84937023038

SN - 0887-6924

VL - 29

SP - 1605

EP - 1608

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this